Joosten E A G, de Jong C A J, de Weert-van Oene G H, Sensky T, van der Staak C P F
Novadic-Kentron, Network for Addiction Treatment Services, Vught, The Netherlands.
Psychother Psychosom. 2009;78(4):245-53. doi: 10.1159/000219524. Epub 2009 May 21.
In the last decades, shared decision-making (SDM) models have been developed to increase patient involvement in treatment decisions. The purpose of this study was to evaluate a SDM intervention (SDMI) for patients dependent on psychoactive substances in addiction health care programs. The intervention consisted of a structured procedure to reach a treatment agreement and comprised 5 sessions.
Clinicians in 3 treatment centres in the Netherlands were randomly assigned to the SDMI or a standard procedure to reach a treatment agreement.
A total of 220 substance-dependent patients receiving inpatient treatment were randomised either to the intervention (n = 111) or control (n = 109) conditions. Reductions in primary substance use (F((1, 124)) = 248.38, p < 0.01) and addiction severity (F((8)) = 27.76, p < 0.01) were found in the total population. Significant change was found in the total population regarding patients' quality of life measured at baseline, exit and follow-up (F((2, 146)) = 5.66, p < 0.01). On the European Addiction Severity Index, SDMI showed significantly better improvements than standard decision-making regarding drug use (F((1, 164)) = 7.40, p < 0.01) and psychiatric problems (F((1, 164)) = 5.91, p = 0.02) at 3-month follow-up.
SDMI showed a significant add-on effect on top of a well-established 3-month inpatient intervention. SDMI offers an effective, structured, frequent and well-balanced intervention to carry out and evaluate a treatment agreement.
在过去几十年中,已开发出共享决策(SDM)模型以提高患者在治疗决策中的参与度。本研究的目的是评估成瘾医疗保健项目中针对依赖精神活性物质患者的共享决策干预(SDMI)。该干预包括达成治疗协议的结构化程序,共5个环节。
荷兰3个治疗中心的临床医生被随机分配接受SDMI或达成治疗协议的标准程序。
共有220名接受住院治疗的物质依赖患者被随机分为干预组(n = 111)或对照组(n = 109)。在总体人群中发现主要物质使用量减少(F((1, 124)) = 248.38,p < 0.01)以及成瘾严重程度降低(F((8)) = 27.76,p < 0.01)。在总体人群中,从基线、出院时及随访时测量的患者生活质量方面发现了显著变化(F((2, 146)) = 5.66,p < 0.01)。在欧洲成瘾严重程度指数上,在3个月随访时,SDMI在药物使用(F((1, 164)) = 7.40,p < 0.01)和精神问题(F((1, 164)) = 5.91,p = 0.02)方面显示出比标准决策有显著更好的改善。
SDMI在成熟的3个月住院干预基础上显示出显著的附加效果。SDMI为执行和评估治疗协议提供了一种有效、结构化、频繁且平衡良好的干预措施。